Biora Therapeutics received an Issue Notification from the U.S. Patent and Trademark Office for a patent related to the treatment of gastrointestinal disorders through targeted delivery of JAK inhibitors for its NaviCap targeted oral delivery platform under development. US Patent Application No. 17/313,339, entitled “Treatment of a Disease of the Gastrointestinal Tract with a JAK Inhibitor and Devices,” will issue as US Patent No. 11,857,669 on January 2, 2024. The patent is directed to methods of treating a GI disease by delivering a therapeutically effective amount of a JAK inhibitor at a desired location in the GI tract, where the therapeutically effective amount of the JAK inhibitor is less than an amount that is effective when the JAK inhibitor is administered systemically. The patent covers many JAK inhibitors, including those that are approved or in development for a range of indications. The NaviCap ingestible device platform is protected by a patent portfolio consisting of 30 patent families, including 86 granted patents and 81 pending applications. Included in the NaviCap portfolio are 34 granted patents and 6 pending applications directed to the device’s proprietary autonomous localization technology and to various therapeutic targets for the treatment of inflammatory bowel disease, including, but not limited to, Janus kinases, TNF-alpha, integrins, chemokines, IL-12/23, S1P, and IL-10 inhibitors, and the delivery of antibodies, peptides, small molecules, nucleic acids, stem cells, bacterial yeast, or phages to the gastrointestinal tract. Biora’s total corporate portfolio consists of 73 patent families, including approximately 190 issued patents and 135 pending applications filed in major jurisdictions around the world, including the US, Europe, China, Japan, South Korea, Israel, Australia, Canada, and Mexico.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on BIOR:
- Biora Therapeutics Announces New Patent for its NaviCap™ Targeted Oral Delivery Platform
- Biora Therapeutics enters research collaboration for BioJet platform
- Biora Therapeutics Announces New Research Collaboration for the BioJet™ Systemic Oral Delivery Platform
- Biora Therapeutics: FDA clears IND application for BT-600
- Biora Therapeutics Provides Corporate Update and Reports Third Quarter 2023 Financial Results